Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Handling Bioanalytical Raw Data Files – V 2.0

Posted on By

BA-BE Studies: SOP for Handling Bioanalytical Raw Data Files – V 2.0

Standard Operating Procedure for Handling Bioanalytical Raw Data Files in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/171/2025
Supersedes SOP/BA-BE/171/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for the secure handling, retrieval, and archiving of raw data files generated from LC-MS/MS instruments during bioanalytical runs in BA/BE studies.

2. Scope

This SOP is applicable to all raw data files generated from analytical instruments used in the analysis of plasma samples during bioavailability/bioequivalence studies, including but not limited to LC-MS/MS data,

sequence files, and audit trails.

3. Responsibilities

  • Analyst: Ensures accurate generation, naming, and storage of data files post-run.
  • Reviewer/Supervisor: Verifies completeness and correctness of data folders and sequence files.
  • QA: Conducts audits and reviews the archival and access control systems for raw data.
  • IT Administrator: Manages secure backups and controls access permissions.
See also  BA-BE Studies: SOP for Weekend and Holiday Subject Management - V 2.0

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring the traceability, completeness, and secure archival of raw data in compliance with GxP regulations and data integrity requirements.

5. Procedure

5.1 Raw Data File Types and Sources

  1. Raw data includes:
    • Sequence files (.seq, .wiff, .raw)
    • Chromatogram data
    • Instrument logs
    • Audit trails and processing methods
  2. Data may be stored locally on instrument systems or transferred to central servers.

5.2 File Naming and Folder Structure

  1. Use the following naming convention for folders:
    • Format: [StudyCode]/[Analyte]/[BatchID]/[YYYY-MM-DD]
    • Example: BE1245/Metformin/Batch03/2025-04-17
  2. Ensure each folder contains:
    • Sequence file
    • Raw chromatograms
    • Integration results
    • System suitability test results

5.3 Data Transfer and Backup

  1. Upon completion of run, transfer data to the central secured server within 24 hours.
  2. Data must be backed up to:
    • Primary storage (lab server)
    • Secondary offsite/cloud backup
  3. Use checksum or hash validation to confirm data integrity post-transfer.
See also  BA-BE Studies: SOP for Carryover Check in Bioanalytical Runs - V 2.0

5.4 Data Access and Security

  1. Restrict access to raw data to authorized personnel only via password-protected directories.
  2. Maintain access logs indicating user ID, login time, and files accessed.
  3. QA shall periodically review access logs and highlight anomalies.

5.5 Data Review and Locking

  1. Once raw data is reviewed and approved, mark the folder as “locked” and move to read-only format.
  2. Any post-lock changes must be tracked via Change Control procedures.
  3. Review of peak integration, audit trails, and system suitability must be completed before approval.

5.6 Archival and Retrieval

  1. Raw data files must be archived:
    • Digitally on secure servers for at least 5 years or as per regulatory requirements
    • Maintain a copy on archival media (DVD, secure drive)
  2. Archive location must be recorded in Annexure-1: Raw Data Archival Log.
  3. Retrievals for inspection must be documented using Annexure-2: Data Access Request Form.

6. Abbreviations

  • BA/BE: Bioavailability/Bioequivalence
  • GxP: Good Practice (GLP/GCP/GMP)
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
See also  BA-BE Studies: SOP for Room Temperature Monitoring in Sample Collection Areas - V 2.0

7. Documents

  1. Raw Data Archival Log – Annexure-1
  2. Data Access Request Form – Annexure-2

8. References

  • ICH E6(R2): Good Clinical Practice
  • 21 CFR Part 11 – Electronic Records and Signatures
  • FDA Guidance on Data Integrity

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Raw Data Archival Log

Study Code Batch ID Folder Path Archival Date Archived By
BE1245 Batch03 \ServerBA1245Batch03 17/04/2025 Sunita Reddy

Annexure-2: Data Access Request Form

Date User Name Data Requested Purpose Authorized By
18/04/2025 Rajesh Kumar BE1245 Batch03 Internal Audit QA Manager

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP New process QA Head
17/04/2025 2.0 Included backup verification and access log review Regulatory update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: API Manufacturing: SOP for Cleaning and Shutdown of QC Equipment – V 2.0
Next Post: Analytical Method Development: KBr Pellet Method Optimization – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version